Patient characteristics
| Patient ID . | Age, y . | Sex . | Phase at IM start . | Prior treatment . | Time from diagnosis to IM start, mo . | Time to CCyR after starting IM, mo . | PCR-negative sample studied . | Consistently PCR negative . |
|---|---|---|---|---|---|---|---|---|
| 144 | 47 | M | CP | IFN + Ara-C | 7 | 9 | Y | Y |
| 177 | 50 | F | CP | IFN | 21 | 6 | Y | Y |
| 202 | 56 | F | CP | IFN | 15 | 3 | Y | N |
| 222 | 64 | F | CP | IFN | 30 | 9 | Y | N |
| 232 | 58 | M | CP | IFN + Ara-C | 20 | 9 | Y | Y |
| 238 | 62 | M | CP | IFN | 25 | 6 | Y | N |
| 248 | 68 | M | CP | None | 1 | 6 | Y | Y |
| 256 | 40 | M | CP | None | 0.25 | 6 | Y | Y |
| 273 | 41 | F | CP | None | 0.75 | 6 | Y | Y |
| 292 | 41 | F | CP | None | 0.5 | 3 | Y | Y |
| 296 | 66 | M | CP | IFN | 13 | 5 | Y | Y |
| 299 | 59 | F | CP | None | 4 | 6 | Y | N |
| 327 | 37 | M | CP | None | 0.75 | 9 | Y | N |
| 347 | 35 | M | CP | None | 2 | 6 | Y | Y |
| 397 | 44 | F | CP | None | 0.1 | 10 | Y | N |
| 469 | 25 | M | CP | None | 0.1 | 6 | Y | Y |
| 476 | 56 | F | CP | None | 0.1 | 5 | Y | N |
| 833 | 67 | F | CP | IFN | 31 | 34 | N | N |
| 902 | 52 | F | CP | None | 0.0 | 4 | Y | Y |
| 924 | 57 | M | CP | None | 0.1 | 5 | Y | Y |
| Patient ID . | Age, y . | Sex . | Phase at IM start . | Prior treatment . | Time from diagnosis to IM start, mo . | Time to CCyR after starting IM, mo . | PCR-negative sample studied . | Consistently PCR negative . |
|---|---|---|---|---|---|---|---|---|
| 144 | 47 | M | CP | IFN + Ara-C | 7 | 9 | Y | Y |
| 177 | 50 | F | CP | IFN | 21 | 6 | Y | Y |
| 202 | 56 | F | CP | IFN | 15 | 3 | Y | N |
| 222 | 64 | F | CP | IFN | 30 | 9 | Y | N |
| 232 | 58 | M | CP | IFN + Ara-C | 20 | 9 | Y | Y |
| 238 | 62 | M | CP | IFN | 25 | 6 | Y | N |
| 248 | 68 | M | CP | None | 1 | 6 | Y | Y |
| 256 | 40 | M | CP | None | 0.25 | 6 | Y | Y |
| 273 | 41 | F | CP | None | 0.75 | 6 | Y | Y |
| 292 | 41 | F | CP | None | 0.5 | 3 | Y | Y |
| 296 | 66 | M | CP | IFN | 13 | 5 | Y | Y |
| 299 | 59 | F | CP | None | 4 | 6 | Y | N |
| 327 | 37 | M | CP | None | 0.75 | 9 | Y | N |
| 347 | 35 | M | CP | None | 2 | 6 | Y | Y |
| 397 | 44 | F | CP | None | 0.1 | 10 | Y | N |
| 469 | 25 | M | CP | None | 0.1 | 6 | Y | Y |
| 476 | 56 | F | CP | None | 0.1 | 5 | Y | N |
| 833 | 67 | F | CP | IFN | 31 | 34 | N | N |
| 902 | 52 | F | CP | None | 0.0 | 4 | Y | Y |
| 924 | 57 | M | CP | None | 0.1 | 5 | Y | Y |
M indicates male; F, female; CP, chronic phase; IFN, IFN-α; Ara-C, cytosine arabinoside; and IM, imatinib mesylate.